Jpmorgan Chase Stock News

JPMorgan Chase & Co. lessened its position in Silvercrest Asset Management Group Inc. (NASDAQ:SAMG) by 40.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,160 shares of the asset managers stock after selling 11,480 shares during the period. JPMorgan Chase & []

JPMorgan Chase & Co. boosted its position in Navigator Holdings Ltd. (NYSE:NVGS) by 15.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,377 shares of the shipping companys stock after buying an additional 3,201 shares during the period. JPMorgan []

JPMorgan Chase & Co. lifted its holdings in Celcuity Inc. (NASDAQ:CELC) by 234,200.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,372 shares of the companys stock after purchasing an additional 9,368 shares during the quarter. JPMorgan Chase & Co.s holdings in Celcuity []

JPMorgan Chase & Co. lessened its holdings in Gatos Silver, Inc. (NYSE:GATO) by 80.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,289 shares of the companys stock after selling 55,969 shares during the period. JPMorgan Chase & Co.s holdings in Gatos Silver were []

JPMorgan Chase & Co. increased its stake in Chimerix, Inc. (NASDAQ:CMRX) by 26.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,240 shares of the biopharmaceutical companys stock after purchasing an additional 5,926 shares during the period. JPMorgan Chase & Co.s holdings []

JPMorgan Chase & Co. reduced its stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) by 43.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 59,786 shares of the companys stock after selling 46,316 shares during the quarter. JPMorgan Chase & Co.s holdings in Cyclerion Therapeutics were []